Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes

There is concern that people with rheumatic disease, often treated with immunosuppressive or immunomodulatory medication, may be at an increased risk of poor outcomes of novel coronavirus disease-2019 (COVID-19). However, hyperinflammation is a major cause of morbidity and mortality in COVID-19 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Grainger, Rebecca, Machado, Pedro M., Robinson, Philip C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
1
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756169/
https://www.ncbi.nlm.nih.gov/pubmed/33468418
http://dx.doi.org/10.1016/j.berh.2020.101657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756169/
https://www.ncbi.nlm.nih.gov/pubmed/33468418
http://dx.doi.org/10.1016/j.berh.2020.101657

Ejemplares similares